PL3727429T3 - Leczenie zaburzeń autonomicznych toksyną botulinową - Google Patents
Leczenie zaburzeń autonomicznych toksyną botulinowąInfo
- Publication number
- PL3727429T3 PL3727429T3 PL18825698.6T PL18825698T PL3727429T3 PL 3727429 T3 PL3727429 T3 PL 3727429T3 PL 18825698 T PL18825698 T PL 18825698T PL 3727429 T3 PL3727429 T3 PL 3727429T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- botulinum toxin
- autonomic disorders
- autonomic
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306840 | 2017-12-20 | ||
| PCT/EP2018/086261 WO2019122166A1 (en) | 2017-12-20 | 2018-12-20 | Treatment of autonomic disorders with botulinum toxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3727429T3 true PL3727429T3 (pl) | 2025-08-25 |
Family
ID=61027399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18825698.6T PL3727429T3 (pl) | 2017-12-20 | 2018-12-20 | Leczenie zaburzeń autonomicznych toksyną botulinową |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20200377872A1 (pl) |
| EP (2) | EP3727429B1 (pl) |
| JP (4) | JP7162059B2 (pl) |
| KR (1) | KR20200100625A (pl) |
| CN (1) | CN111491659A (pl) |
| AR (1) | AR113983A1 (pl) |
| AU (2) | AU2018392818C1 (pl) |
| BR (1) | BR112020005186A2 (pl) |
| CA (1) | CA3083069A1 (pl) |
| DK (1) | DK3727429T3 (pl) |
| EA (1) | EA202091527A1 (pl) |
| ES (1) | ES3036736T3 (pl) |
| FI (1) | FI3727429T3 (pl) |
| HU (1) | HUE071806T2 (pl) |
| MA (1) | MA51279A (pl) |
| MX (1) | MX2020006043A (pl) |
| PL (1) | PL3727429T3 (pl) |
| PT (1) | PT3727429T (pl) |
| SG (1) | SG11202002876WA (pl) |
| TW (1) | TWI810228B (pl) |
| WO (1) | WO2019122166A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202001353D0 (en) * | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
| TWI825396B (zh) * | 2020-03-16 | 2023-12-11 | 英商艾普森生物製藥有限公司 | 肢體痙攣之治療 |
| GB202206353D0 (en) * | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| JP2025534349A (ja) * | 2022-09-30 | 2025-10-15 | イプセン バイオファーム リミテッド | 膀胱痛症候群の治療 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0328060D0 (en) | 2003-12-04 | 2004-01-07 | Sod Conseils Rech Applic | Botulinum toxin treatment |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| ATE518882T1 (de) | 2005-09-19 | 2011-08-15 | Allergan Inc | Mit clostridientoxin aktivierbare clostridientoxine |
| UA116985C2 (uk) | 2012-05-30 | 2018-06-11 | Президент Енд Феллоуз Оф Гарвард Колледж | Рекомбінантний ботулінічний нейротоксин |
| GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| PT3274364T (pt) * | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| GB201505306D0 (en) * | 2015-03-27 | 2015-05-13 | Ipsen Biopharm Ltd | Chimeric polypeptides |
| TW201718627A (zh) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| IL263058B2 (en) * | 2016-06-08 | 2023-11-01 | Childrens Medical Center | Engineered botulinum neurotoxins |
| CN109106957A (zh) * | 2018-11-08 | 2019-01-01 | 自贡德西玛医疗设备有限公司 | 一种旋转增效的高温消毒系统 |
-
2018
- 2018-12-06 TW TW107143840A patent/TWI810228B/zh active
- 2018-12-19 AR ARP180103723A patent/AR113983A1/es unknown
- 2018-12-20 AU AU2018392818A patent/AU2018392818C1/en active Active
- 2018-12-20 EA EA202091527A patent/EA202091527A1/ru unknown
- 2018-12-20 EP EP18825698.6A patent/EP3727429B1/en active Active
- 2018-12-20 EP EP25174628.5A patent/EP4591933A3/en active Pending
- 2018-12-20 KR KR1020207015177A patent/KR20200100625A/ko not_active Ceased
- 2018-12-20 DK DK18825698.6T patent/DK3727429T3/da active
- 2018-12-20 CA CA3083069A patent/CA3083069A1/en active Pending
- 2018-12-20 FI FIEP18825698.6T patent/FI3727429T3/fi active
- 2018-12-20 ES ES18825698T patent/ES3036736T3/es active Active
- 2018-12-20 PT PT188256986T patent/PT3727429T/pt unknown
- 2018-12-20 PL PL18825698.6T patent/PL3727429T3/pl unknown
- 2018-12-20 BR BR112020005186-1A patent/BR112020005186A2/pt unknown
- 2018-12-20 JP JP2020523721A patent/JP7162059B2/ja active Active
- 2018-12-20 MX MX2020006043A patent/MX2020006043A/es unknown
- 2018-12-20 CN CN201880082409.9A patent/CN111491659A/zh active Pending
- 2018-12-20 MA MA051279A patent/MA51279A/fr unknown
- 2018-12-20 WO PCT/EP2018/086261 patent/WO2019122166A1/en not_active Ceased
- 2018-12-20 HU HUE18825698A patent/HUE071806T2/hu unknown
- 2018-12-20 SG SG11202002876WA patent/SG11202002876WA/en unknown
- 2018-12-20 US US16/766,338 patent/US20200377872A1/en not_active Abandoned
-
2022
- 2022-10-14 JP JP2022165316A patent/JP7445725B2/ja active Active
-
2024
- 2024-02-26 JP JP2024026296A patent/JP7659676B2/ja active Active
- 2024-10-13 US US18/914,188 patent/US20250101397A1/en active Pending
-
2025
- 2025-03-27 JP JP2025054116A patent/JP2025098207A/ja active Pending
- 2025-04-01 AU AU2025202320A patent/AU2025202320A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271085A (en) | Bacteria for the treatment of disorders | |
| IL285151A (en) | Methods of treating fgf21-associated disorders | |
| HUE064141T2 (hu) | Azolopirimidin rákkal összefüggõ rendellenességek kezelésére | |
| IL290994A (en) | Methods of diagnosing and treating conduct disorder | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| IL263680A (en) | Combination therapies | |
| IL262852A (en) | Treatment of complement-mediated disorders | |
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| HUE056287T2 (hu) | Pancreatitis kezelése | |
| IL304733A (en) | Improved use of botulinum neurotoxin in the treatment of sialorrhea | |
| EP3334429C0 (en) | HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR | |
| IL255185A0 (en) | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto | |
| LT3307267T (lt) | Išsėtinės sklerozės gydymas | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| IL270900A (en) | Treatment of cutaneous disorders | |
| EP3597225A4 (en) | TREATMENT PROCESS | |
| IL254825A0 (en) | Methods of treatment with taselisib | |
| PL3727429T3 (pl) | Leczenie zaburzeń autonomicznych toksyną botulinową | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| IL280227A (en) | Arimoclomol for treating glucocerebrosidase associated disorders | |
| IL263080B (en) | Treatment of neurological disorders | |
| PL3727423T3 (pl) | Leczenie zaburzeń metabolicznych z użyciem wariantów fgf21 | |
| ITUA20161679A1 (it) | Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi | |
| PL3131549T3 (pl) | Sposób leczenia zaburzeń ruchowych przy użyciu befiradolu | |
| DK3229827T3 (da) | Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme |